Gastrointestinal Drug Market Report Top Manufacturers Promising Targets Have Been Reviewed In Greater Detail Analyzing Trends Of Industry

0
36
Image Credits: https://pharmaphorum.com

Gastrointestinal Drug Market Report is a proficient latest research of the Gastrointestinal Drug industry comprising of leading manufacturers, product types, and market size revenue forecast. In addition, report sheds light on dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed and includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available.

Global revenue for the gastrointestinal market is forecast to grow at a CAGR of 4.45%, from $35.7 billion in 2015 to $48.4 billion in 2022.

Request Sample of Report at: https://www.absolutereports.com/enquiry/request-sample/10399931  

Pipeline Characterized by Emerging Biologic Therapies, While TNF Inhibitors and PPIs Continue to Dominate Therapy Landscape: Global Gastrointestinal Drug Market to 2022 Report covers all gastrointestinal disorders, but there is a particular focus on three key diseases: gastroesophageal reflux disease, irritable bowel syndrome and inflammatory bowel disease. The global gastrointestinal market was valued at $35.7 billion in 2015 and is projected to grow at a compound annual growth rate (CAGR) of 4.45%, reaching $48.4 billion in 2022. Proton pump inhibitors (PPIs) and tumor necrosis factor (TNF)-α inhibitors generate the largest revenues and continue to retain commercial prominence. Key drivers of market growth will be the uptake of recently approved premium products, rising prevalence, and promising late-stage products, including a number of biologic therapies that are expected to be highly valuable.

Disease and disorders involving the gastrointestinal system are among the most common conditions encountered worldwide, and many of them can have a significant impact on quality of life. The direct and indirect socio-economic burden associated with gastrointestinal disorders is profound. The direct costs of medical consultations and treatments in the US for gastroesophageal reflux disease alone are estimated to amount to $9.3 billion, while the indirect costs due to absenteeism and impairment in work performance total $75 billion (Chait, 2010).

View Full Report of Gastrointestinal Drug market: https://www.absolutereports.com/10399931

Despite the significant global socio-economic burden, many gastrointestinal disorders are still poorly understood, and there is a significant unmet need for novel, safe and effective therapies, as treatment options are often lacking, causing many patients to be dissatisfied with their treatment. The unmet need and demand for better treatments and the high prevalence of digestive conditions make the gastrointestinal market an attractive candidate for therapeutic development.

Opportunities and Scope of Report:

There are 937 gastrointestinal pipeline products in active development, of which small molecules and biologics account for 53% and 38%, respectively.

  • Which molecular targets are most prominent within the pipeline?
  • How do the key indications differ in terms of molecule type?
  • How does the composition of the pipeline compare with that of the existing market?
  • What mechanisms of action are most common for pipeline drugs?

The gastrointestinal market landscape is expected to change substantially with the advent of promising novel pipeline products.

  • Which products will be the biggest drivers for market growth?
  • Will the current market leaders retain their dominance over the forecast period, and how is their revenue share of the gastrointestinal market set to change?
  • What CAGR will these companies register in the forecast period?

LEAVE A REPLY